siRNA & Oligonucleotide Licensing Landscape 2026

The Thesis: A Modality Comes of Age

For two decades, RNA-silencing drugs were a science story in search of a commercial one. The biology was elegant — switch off a disease-causing gene at the messenger-RNA level, upstream of the protein — but delivery problems and a thin clinical record kept the modality penned into rare disease. That penning is over. The oligonucleotide therapeutics market is now generally valued in the range of 6 to 7 billion US dollars in 2025, with forecasters such as MarketsandMarkets projecting roughly 17.7 billion dollars by 2030 at about a 20% compound annual growth rate. Those numbers do not come from more rare-disease launches; they come from the modality breaking into the largest markets in medicine — cholesterol, hypertension, and the cardiometabolic frontier behind the obesity wave.

For a BD team, this is the more important framing than any single drug. A modality that has proven it can silence a liver target durably, dose twice a year, and clear the FDA is no longer a science bet — it is a platform that throws off licensable assets faster than any one company can develop them. That is why the deal flow has become the real story, and why a growing share of those assets now originate in China. This guide maps the modality the way a dealmaker reads it: what you are buying, who makes it, what it costs, and where the next assets will come from.

siRNA vs ASO: What You Are Buying

The two workhorse chemistries sit under one commercial umbrella, but the distinction matters in diligence because it drives durability, dosing, and which tissues a candidate can reach.

• Small interfering RNA (siRNA). Double-stranded. It co-opts the cell’s own RNA-interference machinery — loading into the RISC complex — to catalytically cleave a target messenger RNA. Because the machinery is catalytic, silencing is potent and exceptionally durable: for liver targets, dosing as infrequent as twice a year.
• Antisense oligonucleotide (ASO). Single-stranded. It binds the target RNA directly, then either recruits the enzyme RNase H to degrade it or sterically blocks splicing and translation. ASOs offer more chemical flexibility and have reached tissues that siRNA historically could not — most notably the central nervous system via intrathecal delivery.

The practical read for a licensor: an siRNA liver asset is buying durability and a convenient dosing schedule that drives adherence in chronic disease, while an ASO program may be buying access to a harder tissue or a splice-modulation mechanism that siRNA cannot replicate. Neither is universally superior — and most of the large platform deals deliberately span both, because the value is in the target and the delivery, not the strand count.

GalNAc and the Liver Beachhead

The single technology that turned RNA silencing into a commercial modality is GalNAc conjugation. Attaching a triantennary N-acetylgalactosamine ligand to the oligonucleotide lets it bind the asialoglycoprotein receptor, which is densely and almost exclusively expressed on liver hepatocytes. The result is targeted, efficient uptake into the liver after a simple subcutaneous injection — replacing the lipid-nanoparticle infusions that the first generation (Alnylam’s Onpattro) required.

GalNAc is why subcutaneous dosing now dominates the modality and why the liver became the beachhead. And the liver is not a small prize: it is the metabolic hub for cholesterol (apolipoprotein synthesis), for lipoprotein(a), for triglyceride regulation, and for angiotensinogen — the protein at the top of the blood-pressure cascade. In other words, GalNAc handed the modality the door to cardiometabolic disease, the highest-volume therapeutic territory in the industry. The strategic consequence is that the most valuable oligonucleotide assets today are GalNAc-conjugated siRNAs against liver-expressed cardiometabolic targets — and that is exactly the profile of the largest recent deals.

The Approved Products

The clinical record is now substantial and spans both chemistries. The approved roster is what gives the modality its de-risked status — and what the platform deals are implicitly priced against.

Two milestones in this table mark the modality’s coming-of-age. Amvuttra’s 2025 FDA approval to reduce cardiovascular death and hospitalization in ATTR cardiomyopathy moved an siRNA from a rare polyneuropathy into a far larger cardiology population — the first RNAi therapeutic to carry that kind of outcomes label. And Tryngolza (December 2024) was Ionis’s first wholly owned independent launch in a 35-year history, signaling that the antisense pioneer intends to commercialize, not just license. Leqvio, meanwhile, is the proof that a silencing drug can scale into a primary-care cardiometabolic market.

The Platform Leaders

The competitive field is more concentrated than in most modalities — delivery and chemistry IP is hard-won — which makes the handful of credible platforms the natural counterparties for any in-licensing effort.

• Alnylam. The category pioneer and the only company with a deep approved RNAi portfolio (five products, counting the Novartis-partnered Leqvio). It set the GalNAc standard and has graduated from rare disease into cardiology with Amvuttra and into hypertension via the Roche zilebesiran partnership.
• Ionis. The antisense leader, with the longest track record (Spinraza), a GalNAc-conjugated franchise (Wainua, Tryngolza), and a shift toward independent commercialization.
• Arrowhead Pharmaceuticals. The modality’s most prolific licensor. Its TRiM platform has spun out partnerships with Amgen (olpasiran for Lp(a)), Sarepta, Sanofi, GSK, Takeda and Novartis, and its own first product, plozasiran, has advanced in familial chylomicronemia syndrome with a broader hypertriglyceridemia opportunity behind it.
• Silence Therapeutics. A UK-based siRNA specialist (mRNAi GOLD platform) with a long-running AstraZeneca collaboration and zerlasiran, an Lp(a)-lowering siRNA that showed roughly 90% median Lp(a) reduction in Phase 2.
• Dicerna (Novo Nordisk). Acquired by Novo Nordisk for about 3.3 billion dollars in 2021, bringing the GalXC RNAi engine in-house — a marker of how strategically big pharma now values owning a silencing platform rather than renting one.

For the cross-modality context — how siRNA stacks up against cell and gene therapy in deal terms and risk — see our gene therapy market and licensing deals analysis.

The Deal Wave

The clearest evidence that the modality has arrived is the money. The deals span outright platform acquisition, single-asset co-development, and — increasingly — cross-border in-licensing.

Two patterns are worth pulling out for anyone underwriting this space. First, the therapeutic concentration is overwhelmingly cardiometabolic — cholesterol, Lp(a), triglycerides, hypertension. The liver beachhead and the global cardiometabolic demand wave have steered nearly all the big capital into the same handful of validated targets, which means the marquee assets are competitive and richly priced. Second, the upfront-to-total ratio is small, as it is across biopharma: a 5.2 billion dollar Novartis–Argo headline carries a 160 million dollar upfront, so the great majority of value is contingent on milestones and must be discounted hard. We maintain the running cross-modality view in the biotech licensing deal tracker.

Beyond the Liver: The Next Frontier

If GalNAc opened the liver, the next value inflection is extrahepatic delivery — reaching tissues the conjugate cannot. The most advanced frontier is the central nervous system, where ASOs already have a foothold (Spinraza, Qalsody) via intrathecal dosing, and where multiple platforms are racing to deliver silencing drugs to the brain more conveniently. Neurodegeneration — Huntington’s, ALS, Alzheimer’s-associated targets — is the prize, because it pairs clear genetic targets with enormous unmet need.

The other expansion vector is deeper into cardiometabolic and into obesity-adjacent biology. The same liver toolkit is being aimed at new lipid and metabolic nodes, and early-stage programs are probing whether durable RNA silencing can complement or extend the incretin (GLP-1) franchises that now dominate metabolic disease — for the deal dynamics of that adjacent wave, see our GLP-1 licensing landscape. The strategic point for a BD team: liver cardiometabolic assets are where today’s competition and pricing are hottest, while extrahepatic and CNS programs are where the asymmetric, less-contested entry points still exist for those willing to take earlier-stage delivery risk.

The China Cross-Border Angle

The modality’s most consequential recent shift is geographic. China has built real depth in RNAi chemistry and GalNAc delivery, and paired it with the fast, lower-cost clinical execution that gets a liver-targeted candidate to human proof-of-concept quickly. The result is a string of large licensing deals flowing west:

• Novartis–Argo Biopharma. Shanghai-based Argo (founded 2021, with its RADS RNAi platform) signed an initial deal in January 2024 — a 185 million dollar upfront for ex-Greater China rights to a cardiovascular siRNA plus options — then a far larger expansion in 2025: a 160 million dollar upfront with milestones that could reach roughly 5.2 billion dollars across additional cardiometabolic targets.
• Genentech (Roche)–SanegeneBio. SanegeneBio, an RNAi company operating across the US and China with a proprietary GalNAc platform and multiple clinical-stage candidates, licensed an RNAi program to Genentech in a deal worth up to about 1.5 billion dollars.

The pattern is unmistakable: in the modality where delivery IP and clinical speed are the value drivers, Chinese platforms have become a primary origination source — and Western pharma is paying real upfronts and large biobucks to access ex-China or global rights. This is the same out-licensing surge reshaping Chinese biotech across modalities, which we quantify in the China out-licensing report. For an siRNA-focused buyer, the implication is concrete: the next de-risked cardiometabolic asset is as likely to surface in Shanghai or Suzhou as in Cambridge or Basel.

How Dealmakers Should Engage

For a Western company building or extending an oligonucleotide portfolio, the dominant model is the same one playing out in the data: source and license, not build from scratch. Standing up a competitive delivery platform de novo is slow and capital-intensive when validated platforms — increasingly in China — already produce clinic-ready assets. Executing the in-licensing route well comes down to a few disciplines specific to this modality:

• Diligence the delivery and chemistry IP. The differentiated value is in the conjugate, the modifications, and the delivery platform — confirm freedom-to-operate against the dense GalNAc and siRNA-chemistry patent thicket, not just the target.
• Confirm durability and the dosing claim. The commercial case for an siRNA often rests on infrequent dosing and adherence; the supporting pharmacodynamic and safety data must hold up to FDA and EMA scrutiny.
• Read the therapeutic-area competition. Cardiometabolic liver targets are crowded and expensive; map whether a candidate is genuinely differentiated or a fast-follow before pricing it.
• Structure for cross-border reality. For China-origin assets, territory splits (ex-China versus global), milestone and royalty design, and clean data and IP provenance are the difference between a deal that closes and one that stalls in legal review.

This is the core of what Vision Lifesciences does — sourcing, diligencing, and structuring cross-border modality deals. If you are evaluating an siRNA or antisense asset or platform, talk to our team.

The Bottom Line

The siRNA and antisense modality has finished its transition from a science story to a commercial one. The approved roster is deep, the liver delivery problem is solved, and the assets have moved into the largest markets in medicine — cholesterol, hypertension, and the cardiometabolic frontier. The deal wave reflects it: outright platform acquisitions, multi-billion-dollar co-development pacts, and a rising tide of cross-border licensing.

The most important shift for a dealmaker is where the next assets originate. In a modality defined by delivery IP and clinical speed, Chinese platforms have become a primary source, and the marquee deals — Novartis–Argo, Genentech–SanegeneBio — show Western pharma is willing to pay for ex-China and global rights. The winners will be the teams that can source these assets early, diligence the chemistry and delivery rigorously, and structure deals that hold up across the border. That is precisely the work this firm exists to do. If you are building an RNA-silencing portfolio, start a conversation.

A closing word on how to value these assets, because the modality has two traps. The first is paying for a platform when you are really buying a single liver-targeted candidate: GalNAc-conjugated, ASGPR-mediated delivery to hepatocytes is now well-trodden, so a hepatic siRNA program should be underwritten as an asset, not as a franchise — the platform premium belongs only to teams with validated extrahepatic delivery (CNS, muscle, lung, immune cell), which remains the field’s hardest and most valuable unsolved problem. The second trap is the durability question: an siRNA can be dosed twice a year, which is a commercial gift, but it also means a single safety signal echoes for months, so chronic-dosing safety data deserves disproportionate diligence weight.

For the cross-border buyer specifically, the calculus mirrors the broader China out-licensing wave: a Chinese siRNA developer can reach human proof-of-concept on a liver target faster and more cheaply than a Western peer, then license ex-China or global rights to a partner with the regulatory and commercial reach to finish the job. The discipline is the same as any deal — discount the biobucks, confirm the delivery and chemistry IP is clean and clearly invented by named humans, and pay the premium only for delivery science a competitor cannot simply re-license.